Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

PURPOSE: We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with chemotherapy-naïve (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Argiris, Athanassios, Li, Shuli, Savvides, Panayiotis, Ohr, James P., Gilbert, Jill, Levine, Marshall A., Chakravarti, Arnab, Haigentz Jr, Missak, Saba, Nabil F., Ikpeazu, Chukwuemeka V., Schneider, Charles J., Pinto, Harlan A., Forastiere, Arlene A., Burtness, Barbara
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980834/
https://ncbi.nlm.nih.gov/pubmed/31618129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00555
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados